Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients

Summary

Toll-like receptor-4 (TLR-4) gene polymorphisms have been associated with a lower risk of atherosclerosis. High levels of soluble P-selectin (sP-selectin) and von Willebrand factor predict an increased risk for cardiovascular events and correlate to atherosclerotic risk factors. The relationship between these markers and TLR-4 gene polymorphisms was evaluated in a cohort of consecutive hypercholesterolemic outpatients. TLR-4 gene polymorphisms were detected in 48 out of 330 (14%) patients with hypercholesterolemia. Lipid and inflammatory markers, sP-selectin and von Willebrand were evaluated in carriers and in 96 (ratio 2:1 to cases) age- and sex-matched TLR-4 wild-type patients randomly selected from the same population. A cohort of normocholesterolemic outpatients (n=262) served as the control group.sP-selectin was sensibly lower in carriers of TLR-4 variants as compared to wild-types and controls (89 ng/ ml vs. 162 ng/ml and 163 ng/dl, respectively, p=0.0001). Similarly, carriers showed lower von Willebrand factor values (683 mU/ ml) than wild-types (910 mU/ml; p=0.001). In multivariate analysis, TLR-4 gene polymorphisms were positively associated with sP-selectin, whereas the relationship with von Willebrand factor was no longer significant. HMG-CoA reductase inhibitors reduced sP-selectin and von Willebrand factor levels independently of TLR-4 gene variants. Plasma concentrations of these markers, however, remained lower in carriers of TLR-4 gene polymorphisms even after cholesterol lowering. In conclusion, carriership of Asp299 andThr399IleTLR-4 gene polymorphisms is associated with lower levels of sP-selectin and von Willebrand factor among hypercholesterolemic patients. While the underlying mechanisms remain to be investigated, such an association may indicate a protective effect of TLR-4 variants for atherosclerosis.

Keywords

Toll-like receptor - gene polymorphism - P-selectin - von Willebrand factor - hypercholesterolemia

• References

• 1 Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 2 Hansson GK, Libby P, Schonbeck U. et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
• 3 Michelsen KS, Doherty TM, Shah PK. et al. TLR signalling: an emerging bridge from innate immunity to atherogenesis. J Immunol 2004; 173: 5901-5907.
• 4 Xu XH, Shah PK, Faure E. et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and up-regulated by oxidized LDL. Circulation 2001; 104: 3103-3108.
• 5 Edfeldt K, Swedenborg J, Hanssson GK. et al. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-1161.
• 6 Arbur NC, Lorenz E, Schuttle BC. et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-191.
• 7 Michel O, LeVan TD, Stern D. et al. Systemic responsiveness to lipopolysaccharide and polymorphisms in the toll-like receptor 4 gene in human beings. J Allergy Clin Immunol 2003; 112: 923-929.
• 8 Kiechl S, Lorenz E, Reindl M. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-192.
• 9 Ameziane N, Beillat T, Verpillat P. et al. Association of the toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23: e61-e64.
• 10 van der Graaf C, Kullberg BJ, Joosten L. et al. Functional consequences of the Asp299Gly toll-like receptor- 4 polymorphism. Cytokine 2005; 30: 264-268.
• 11 Boekholdt SM, Agema WRP, Peters RJG. et al. Variants of Toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003; 107: 2416-2421.
• 12 Yang IA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003; 170: 187-190.
• 13 Zee RYL, Hegener HH, Gould J. et al. Toll-like receptor 4 Asp299Gly gene polymorphism and the risk of atherothrombosis. Stroke 2005; 36: 154-157.
• 14 Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004; 92: 459-466.
• 15 Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-2179.
• 16 Ishiwata N, Takio K, Katayama M. et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J Biol Chem 1994; 269: 23708-23715.
• 17 Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103: 491-495.
• 18 Verhaar MC, Beutler JJ, Gaillard CA. et al. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin. J Hypertens 1998; 16: 45-50.
• 19 Jilma B, Fasching P, Ruthner C. et al. Elevated circulating P-selectin in insulin dependent diabetes mellitus. Thromb Haemost 1996; 76: 328-332.
• 20 Hackman A, Abe Y, Insull W. et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334-1338.
• 21 Davi G, Romano M, Mezzetti A. et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998; 97: 953-957.
• 22 Blann AD. Plasma von Willebrand factor: thrombosis, and the endothelium: the first 30 years. Thromb Haemost 2006; 95: 49-55.
• 23 Andonegui G, Kerfoot SM, McNagny K. et al. Platelets express functional Toll-like receptor-4. Blood 2005; 106: 2417-2423.
• 24 Patrignani P, Di Febbo C, Tacconelli S. et al. Reduced thromboxane biosynthesis in carrier of toll-like receptor 4 polymorphisms in vivo. Blood 2006; 107: 3572-3574.
• 25 Puccetti L, Pasqui AL, Pastorelli M. et al. Time-dependent effect of statins on platelet function in hypercholesterolemia. Eur J Clin Invest 2002; 32: 901-908.
• 26 Bickel C, Rupprecht HJ, Blankenberg SG. et al. Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation, and soluble cell-adhesion. Int J Cardiol 2002; 82: 25-31.
• 27 Methe H, Kim JO, Kofler S. et al. Statins decrease toll-like receptor 4 expression and downstream signalling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005; 25: 1439-1445.
• 28 Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. Biotechniques 2001; 31: 22-24.
• 29 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary on the Third Report of the National Cholesterol Educational Program (NECEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.(Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
• 30 Netea MG, Hijmans A, van Wissen S. et al. Tolllike receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolemia. Eur J Clin Invest 2004; 34: 94-99.
• 31 Jilma B, Blann A, Pernerstorfer T. et al. Regulation of adhesion molecules during human endotoxemia. No acute effects if aspirin. Am J Respir Crit Care Med 1999; 159: 857-863.
• 32 Ward JR, Bingle L, Judge HM. et al. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost 2005; 94: 831-838.
• 33 Montrucchio G, Bosco O, Del Sorbo L. et al. Mechanisms of the priming effect of low-dose of lipopolysaccharides on leukocyte-dependent platelet aggregation in whole blood. Thromb Haemost 2003; 90: 872-881.
• 34 Guessous F, Marcinkiewicz M, Polanowska Grabowska R. et al. Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function. Thromb Haemost 2005; 95: 1019-1027.
• 35 Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lypopolysaccharide signalling. J Exp Med 2003; 197: 1787-1791.
• 36 Wurfel MM, Kunitake ST, Lichenstein H. et al. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025-1035.